<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chu X</submitter><funding>National Natural Science Foundation of Chongqing</funding><funding>Postdoctoral Fellowship Program of CPSF</funding><pagination>26901</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12289963</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>UDP-glucose: glycoprotein glucosyltransferase 1 (UGGT1), a key component of the endoplasmic reticulum quality control (ERQC) system, has established roles in metabolic/infectious diseases, but its oncogenic potential remains unclear. UGGT1's expression, genetic alterations, methylation patterns, immune function and interacting genes were evaluated through different bioinformatics databases, and the roles of UGGT1 in breast cancer were validated by in vitro experiments. UGGT1 was significantly overexpressed in most cancers, correlating with advanced stage and poor survival. Variations in its promoter methylation and mutation patterns across cancers were associated with patient outcomes. UGGT1 status (expression/mutation) was significantly associated with immune cell infiltration in the tumo</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Pan-cancer analysis of UGGT1 in human tumors and experimental validation in breast cancer.</pubmed_title><pmcid>PMC12289963</pmcid><funding_grant_id>GZC20242301</funding_grant_id><funding_grant_id>CSTB2024NSCQ-MSX1185</funding_grant_id><pubmed_authors>Huang Y</pubmed_authors><pubmed_authors>Xiang S</pubmed_authors><pubmed_authors>Chu X</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pan-cancer analysis of UGGT1 in human tumors and experimental validation in breast cancer.</name><description>UDP-glucose: glycoprotein glucosyltransferase 1 (UGGT1), a key component of the endoplasmic reticulum quality control (ERQC) system, has established roles in metabolic/infectious diseases, but its oncogenic potential remains unclear. UGGT1's expression, genetic alterations, methylation patterns, immune function and interacting genes were evaluated through different bioinformatics databases, and the roles of UGGT1 in breast cancer were validated by in vitro experiments. UGGT1 was significantly overexpressed in most cancers, correlating with advanced stage and poor survival. Variations in its promoter methylation and mutation patterns across cancers were associated with patient outcomes. UGGT1 status (expression/mutation) was significantly associated with immune cell infiltration in the tumo</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-03-27T17:03:31.238Z</modification><creation>2025-08-28T03:08:53.321Z</creation></dates><accession>S-EPMC12289963</accession><cross_references><pubmed>40707677</pubmed><doi>10.1038/s41598-025-12619-x</doi></cross_references></HashMap>